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It has been demonstrated that oxidative stress has a ubiquitous role in neurodegenerative diseases. Major source of oxidative
stress due to reactive oxygen species (ROS) is related to mitochondria as an endogenous source. Although there is ample
evidencefromtissuesofpatientswithneurodegenerativedisordersofmorphological,biochemical,andmolecularabnormalitiesin
mitochondria, it is still not very clear whether the oxidative stress itself contributes to the onset of neurodegeneration or it is part
of the neurodegenerative process as secondary manifestation. This paper begins with an overview of how oxidative stress occurs,
discussing various oxidants and antioxidants, and role of oxidative stress in diseases in general. It highlights the role of oxidative
stress in neurodegenerative diseases like Alzheimer’s, Parkinson’s, and Huntington’s diseases and amyotrophic lateral sclerosis. The
last part of the paper describes the role of oxidative stress causing deregulation of cyclin-dependent kinase 5 (Cdk5) hyperactivity
associated with neurodegeneration.
1. OxidativeStress: Oxidantsand Antioxidants
Oxidative stress is caused by the imbalance in the production
of ROS and the biological system’s inability to detoxify
those species and repair the resulting damage. The eﬀects
of oxidative stress depend upon its impact on the cellular
system, whether the system is able to handle well and
regain its original state or not. However, high levels of
oxidative stress can cause necrosis, ATP depletion, and
prevention of controlled apoptotic death [1]. In normal
conditions most of the cells are maintained in a reducing
environment preserved by enzymes. Any imbalance in the
normal redox state leads to toxicity via production of free
radicals and peroxides (constituting reactive oxygen and or
nitrogen species) damaging proteins, lipids, and DNA of the
cell.
ROS are of two types: less reactive and aggressive. Most
of these less reactive species are produced at a low level
by normal aerobic metabolism, and the damage they cause
to cells is constantly repaired. However, in some instances
even the less reactive species like superoxide are readily
convertedbyoxidoreductionreactionswithtransitionmetals
or other redox cycling compounds into more aggressive
radical species that cause extensive cellular damage which
includes damage inﬂicted on DNA [2]. Like in mammalian
cells as a consequence of aerobic respiration within the
mitochondria, superoxide is generated and sequentially
reduced to hydrogen peroxide and hydroxyl radicals which
confer a long-term eﬀect on DNA by causing severe damage
which ultimately leads to mutations [3].
ROS plays an important role in cell signaling, a process
termed redox signaling. Thus, to maintain proper cellular
homeostasis, a balance must be struck between reactive
oxygen production and consumption. Excessive ROS or free
radicals need to be either quenched by converting them into
metabolically nondestructive molecules or be scavenged/
neutralizedrightaftertheirformation.Thisprotectivemech-
anismiscalledtheantioxidantdefensesystempreventingfree
radical mediated damage of cells leading to various diseases
and aging [4].
The most common naturally occurring anti-oxidants
are Vitamin A (retinol), C (ascorbic acid), and E (toco-
pherol), besides polyphenol antioxidants like ﬂavonoids.
Some enzymes also play an important role in combating the
oxidative stress and one of the best studied is superoxide
dismutase (SOD).Catalase, glutathione peroxidase, aldehyde2 Advances in Pharmacological Sciences
dehydrogenases, and sulﬁredoxin all belong to the class of
enzymatic antioxidants [5, 6]. The use of antioxidants to
prevent diseases is highly controversial as there are some
studiesthatalsosuggestasecondarysideaﬀectofuseofthese
antioxidants.
2. OxidativeStressand Diseases
As previously mentioned the imbalance between the reactive
oxygen/nitrogen species formed and quenched leads to the
cell/tissue damage ultimately becoming the cause of many
diseases. In humans, oxidative stress is associated with
diseasesindiﬀerentways.Oxidativestresscouldbegenerated
as a secondary eﬀect of a preexisting diseased condition or
could be the central cause of the disease itself.
Besides being implicated in aging by the accumulation
of the ROS and mutations in the mitochondrial DNA
(mtDNA), oxidative stress is associated with various patho-
logical conditions. It plays a central role in chronic lung
disease (CLD) which is usually found in the preterm infants
subjected to high oxygen concentration [7, 8]. High level of
inﬂammation and infection and lower level of antioxidants
in these infants lead to development of CLD. Tissue injury
is also caused by oxidative stress following irradiation and
hyperoxia. Both hypoxia and hyperoxia are contributors to
increase in ROS. Abundant evidence has demonstrated that
oxidative stress is a key player in ischemia due to oxygen
reperfusioninjuryfollowinghypoxia,leadingtobothcardio-
vascular diseases and strokes [9, 10]. Excessive free radicals
are found in patients of chronic fatigue syndrome (CFS)
[11]. Diabetes initiated due to hyperglycemia has a wide
spectrum of disease manifestations as it leads to increased
susceptibility of oxidative stress ultimately damaging various
organs [12–16]. Endothelial cell dysfunction in diabetic
patients is also associated with less production of nitric oxide
(NO) important in enabling relaxed state of arterial vessels.
Upon administration of antioxidants like SOD and catalase,
endothelial cell function is improved indicating oxidative
stress as an important secondary factor in diabetes [12].
3. Oxidative Stress in Neurodegeneration
One of the most metabolically active organs of the body
is the brain, including the spinal cord comprising central
nervous system (CNS), which, even at rest, utilizes an
estimated 20% of the total oxygen uptake. During active
state this percentage substantially increases and in order
to carry out normal physiological actions, it requires an
uninterrupted oxygen-rich blood supply. Any blockage or
deprivation of this oxygen supply even for a few seconds
can have severe and irreversible detrimental eﬀect to the
cells of brain (both neurons and glia). Consumption of
oxygen leads to production of free radicals and the brain
requirement for higher amount of oxygen leads to even
higher number of reactive oxygen/nitrogen species. Though
CNS has high requirement for oxygen but unexpectedly, is
relatively deﬁcient in the enzymes that metabolize a number
of oxygen-based reactants to innocuous species [17]. On
the contrary, CNS is highly enriched with polyunsaturated
fatty acids which are readily oxidized by toxic oxygen
derivatives [18]. Additional disadvantage is the presence of
the blood-brain barrier, which is designed to protect the
brain from toxins by limiting their diﬀusion into neurons
and glia but also prevents/reduces the uptake of some
antioxidants like vitamin E, into the brain. These features
create an additive eﬀect making the neurons and glia highly
susceptible to destruction by free radical species. Progressive
loss/damage (by these radicals) of structure and function
of neurons caused is called as neurodegeneration. Being
the power house of the cell, mitochondria are directly
associated and susceptible to oxidative stress. This is not
only due to its association with ROS but also due to the
fact that mitochondria is not protected with histones and
is ineﬃciently repaired leading to high mutation rates in
mitochondrial DNA (mtDNA). There has been increasing
evidence suggesting that mutations acquired during ageing
by mtDNA contribute to physiological decline occurring
with age and age-related neurodegeneration [7]. Therefore,
oxidative stress is an important factor in neurodegenerative
diseases, as the damage of the neurons could be due to either
an increase in oxidative process or a decrease in anti-oxidant
defenses or both. Although it is extremely diﬃcult to distin-
guish whether mitochondrial-derived oxidative stress is the
primary cause of toxicity or just reﬂect the consequence of
neurodegeneration, recent evidences indicate that oxidative
stress is the primary event [7].
Among others the three main neurodegenerative diseases
are Alzheimer’s disease (AD), Parkinson’s disease (PD),
and amyotrophic lateral sclerosis (ALS) which are not only
sporadic, but also have rare familial forms. These diseases
occur mainly as sporadic (90%) where as the familial cause
is usually limited (10%). Sporadic forms occur due to
a complicated and heterogeneous mixture of hereditary,
environmental factors, and lifestyle stresses. In contrast
Huntington’s disease (HD), another neurodegenerative dis-
order is completely hereditary. HD is predominantly inher-
ited and is strictly autosomal disorder. In the following
sections role of oxidative stress in all the above-mentioned
neurodegenerative disorders is brieﬂy described.
3.1. Oxidative Stress in Alzheimer’s Disease. Clinically, Alz-
heimer’s disease (AD) is characterized as a late-onset, age-
dependent, progressive cognitive decline which results in
irreversible loss of neurons especially in the cortex and
hippocampus. The major pathological hallmarks of AD are
the formation of extracellular senile plaques due to amyloid
beta 42 peptide (Aβ42) aggregates and the intracellular neu-
roﬁlament tangles (NFT) formed by hyperphosphorylated
microtubuleassociatedprotein,tau(τ)[19].InAD,oxidative
stress has been associated as one of the earlier events. Due to
oxidative stress, processing of APP or τ could be altered via
activation of diﬀerent signaling pathway.
Usually most of the AD cases are late onset and sporadic
butthereare5–10%familialAD(FAD)occurringasanearly-
onset and in an autosomal-dominant manner. FAD can be
caused due to mutations in three genes namely, amyloid
precursor protein (APP), presenilin 1, and 2 (PS1, PS2).
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of APP is initiated by α-secretase followed by γ-secretase
to yield nonamyloidogenic fragments [20]. Mutations in
APP causes the altered proteolytic processing replacing α-
secretase by β-secretase (BACE1), followed by γ-secretase
to yield amyloidogenic Aβ42 which aggregates to form
insoluble plaques. Various cell culture studies have shown
Aβ42 causes toxicity and induces cell death via apoptosis
[21].
In contrast to senile plaques, NFTs are so far not
associated with mutations but are due to modulations of
kinase and phosphatase activities. Normally τ functions to
regulate microtubule (MT) assembly and transport. Where
as in AD τ is hyperphosphorylated and dissociates from
MT, resulting in destabilizing MTs and impairment of
axonal transport. The phospho-τ aggregates form the paired
helical ﬁlaments (PHFs) which further combine to form
the insoluble NFTs [22]. Abnormal hyperphosphorylation
o ft a ui sar e ﬂ e c t i o no fb o t ha na b n o r m a la c t i v a t i o no f
kinases, as well as decreased phosphatase activity [23].
Among various kinases, cyclin-dependent kinase 5 (Cdk5)
plays a major role in causing aberrant hyperphosphorylation
(discussed later in this review). Pin 1 plays an important
role in post phosphorylation of proline-directed Ser/Thr-
residues involved in regulating protein function. In cell
culture, inhibition of Pin1 reduces oxidative stress-induced
apoptosis [24]. Conformational changes catalyzed by Pin1
aﬀect both APP and tau processing. In animal studies,
Pin1 knockout mice show increase in amyloidogenic APP
processing thereby increasing the levels of Aβ42 and also
exhibit tau hyperphosphorylation, neuronal degeneration,
motor, and behavioral deﬁcits [25, 26].
Hyperphosphorylated τ is one of the major causes of
AD pathology as it not only fails in its normal function of
stabilizing microtubules, but also exhibits a “gain of toxic
function” due to its sequestering normal τ.A b s e n c eo f
normal τ results in the disruption of microtubules [27, 28].
Hyperphosphorylated τ accumulates to form the insoluble
intraneuronal PHF-τ which could reﬂect inhibitory binding
of oxidatively damaged protein to the proteasome. Under
physiological conditions any aggregate which could be a
potential toxic tothe systemis cleaned upby the proteasome.
Inhibition of this cleanup process by the proteasome is
suﬃcient to induce neuronal degeneration and death [29].
Also, various evidences suggest that at least in some part
formation of the highly insoluble NFT is associated with
oxidative stress [30, 31]. For the past two decades based
on various mouse models and human clinical trials, much
therapeutics are being employed to ﬁght against AD starting
from the use of antioxidants, neurotrophins, and statins to
the use of hormone replacement and gene therapy [32].
However, the most eﬀective drug treatment or regimen is
yet to be determined as all the current therapies either have
strong side eﬀects or are not very eﬀective.
3.2. Oxidative Stress in Amyotrophic Lateral Sclerosis. Amy-
otrophic lateral sclerosis (ALS) is clinically characterized by
progressive weakness, atrophy, and spasticity of muscle tis-
sue. Pathologically, ALS is an adult-onset neurodegenerative
disease reﬂecting degeneration of upper and lower motor
neurons in the cortex, brainstem, and spinal cord [33].
Like AD, ALS also occurs as both minor familial forms
(fALS) and major (about 90%) sporadic forms (sALS). The
major genetic defect accounting for about 3–20% of fALS
is due to the mutation in the gene encoding ubiquitous
enzyme Cu/Zn-superoxide dismutase (SOD-1). There have
been more than 100 mutations identiﬁed in SOD-1 genes.
Besides SOD-1 some of the other genes related to fALS
include Alsin (ALS2), VAMP-associate protein B (VAPB),
dynactin (DCTN1), TAR DNA-binding protein 43 (TDP-
43), fused in sarcoma protein (FUS), and lipid phosphatase
FIG4 (FIG4). Studies carried out on the postmortem tissue
from sALS and fALS patients clearly show an accumulation
of oxidative damage to proteins, lipids, and DNA indicating
a direct role of oxidative stress in ALS [34–36]. Also, ALS is
multifactorialpathogeneticdiseaseoccurringduetonotonly
oxidative stress but also excitotoxicity, aggregate formation,
inﬂammation, growth factor deﬁciency, and neuroﬁlament
disorganization,makingALSacomplexdiseaseespeciallyfor
its amelioration [37].
In order to better understand the ALS pathogenesis,
most of the recent studies have focused on mouse models
that express the mutant human SOD1 forms. These animals
experience age-dependent motor neuron degeneration with
cellular and biochemical damage to nerve ﬁbers and spinal
cord tissue as well as increased protein and lipid oxida-
tion [38]. Transgenic mice overexpressing the G93ASOD1
mutation has impaired mitochondrial energy metabolism in
the brain and spinal cord at the onset of the disease, also
there is a transient increase in the vacuolar mitochondrial
degeneration preceding motor neurons death [39, 40]. All
these evidences point towards involvement of the mito-
chondrial abnormalities triggering the onset of ALS. Recent
reports have shown evidence of localization of SOD1 to
mitochondria only in aﬀected tissues and preferentially for
mutSOD1 and therefore modulate mitochondrial functions
[41]. MutSOD1 may interfere with the elements of the
electron transport chain (ETC) to generate toxic ROS via
aberrant superoxide chemistry and to promote oxidative
damage to mitochondrial proteins and lipids [42, 43]. Mut-
SOD1 may also disrupt mechanisms by which mitochondria
buﬀer cytosolic calcium levels.
With evidences from the mutSOD1 mouse model, the
most accepted theory is that the diﬀerent point mutations
create a misfolding defect, leading to small amyloid-like
aggregates that appear in late stages of the disease. These
m i s f o l d e da g g r e g a t e dp r o t e i n sc o u l dp r o d u c et o x i ce ﬀect
towards neurons, similar to the neurotoxicity that arises in
other amyloidoses [44, 45]. Misfolded aggregates are insolu-
bleandarenotclearedbyproteasomaldegradation,therefore
they eventually impair and ultimately overwhelm the system
[46, 47]. MutSOD1 aggregates are accumulated in the outer
mitochondrial membrane and may block the protein import
machines, TOM and TIM [41]. Also, mutSOD1 species
bind and sequester mitochondrial Bcl-2 and cytosolic heat-
shock proteins rendering them unavailable for antiapoptotic
functions [48, 49].
Similar to mutSOD-1, more evidence propose alteration
in proteins related to mRNA metabolism leading to protein4 Advances in Pharmacological Sciences
misfolding as a salient feature of ALS pathogenesis [50,
51]. In various sALS and fALS cases, abnormal subcellular
distribution and cytoplasmic aggregation of TAR DNA
binding protein (TDP-43) is widely reported along with
frontotemporal lobar degeneration [52, 53]. Under normal
conditions, TDP-43 regulates diﬀerent processes related to
geneexpressionincludingtranscription,splicing,andmRNA
stability through RNA and DNA binding activities [50, 51,
54]. Proteomic analysis of the TDP-43 revealed associations
with proteins related to RNA metabolism [55]. Also, TDP-
43 interacts with components of stress granules and under
oxidative stress TDP-43 redistributes itself to stress granules;
however, the biological relevance of these observations is
n o tc l e a ry e t[ 55, 56]. Most ALS linked mutations in TDP-
43 are mapped to the C-terminal glycine-rich region, which
is involved in protein–protein interactions between TDP-
43 and other ribonuclear proteins [57]. In ALS and fron-
totemporal lobar degeneration derived tissue, C-terminal
fragments of TDP-43 are speciﬁcally accumulated and have a
high tendency to aggregate into intracellular inclusions [52].
Transgenic mice expressing human mutant TDP-43 develop
aprogressiveandfatalneurodegenerativediseasereminiscent
of ALS, showing motor neuron loss, motor impairment,
muscular atrophy, axonal degeneration, and mitochondrial
dysfunction [53, 58]. Also, speciﬁc neuronal populations in
the frontal cortex and the spinal cord of this mouse model
show accumulation of ubiquitinated protein aggregates,
suggesting that expression of TDP-43 mutants results in
accumulation of misfolded proteins [53].
Theabovedatasuggeststhatbothatoxicgainoffunction
due to protein aggregation/mislocation together with a loss
of normal biological function upon mutations contribute to
diseasepathogenesis.Therehavebeenmixedresultsofinvivo
studies in the generation of ROS and oxidative damage, and
trials of antioxidant therapies have been disappointing [37].
If protein misfolding is the major cause of SOD1-ALS or
TDP-43 associated pathogenesis, then the drugs that could
stabilize SOD1 or other proteins against misfolding would
be a better therapeutic approach. Like in AD, it is unclear
as to what extent potential therapeutic strategies based on
the mouse models will translate to treatment of the human
disease.
3.3. Oxidative Stress in Parkinson’s Disease. Parkinson’s
disease (PD) is a common neurodegenerative movement
disorderandisclinicallycharacterizedbyprogressiverigidity,
bradykinesia, and tremor. Pathologically PD is characterized
by loss of melanin-pigmented nigral neurons accompanied
by depletion of dopamine in the striatum and the presence
of Lewy bodies [59, 60]. Lewy bodies are detergent-insoluble
and eosinophilic ﬁlamentous intraneuronal inclusions usu-
ally positive for ubiquitin and α-synuclein [61]. Although
many evidences suggest that there is not much diﬀerence
between the sporadic and the rare familial forms of PD, yet
the exact molecular mechanism of the pathogenesis is still
unclear. Like other neurodegenerative disorders, mitochon-
drial dysfunction, oxidative damage, environmental factors,
and genetic predisposition may all be involved together in
both sporadic as well as familial PD.
Linkage analysis has led to the discovery of pathogenic
mutations or polymorphisms in mtDNA in nine genes that
mayaccountforasmanyas5–10%ofthecasesoffamilialPD.
Out of these genes, two are autosomal dominant (coding for
α-synuclein and dardarin) and three are autosomal recessive
(including parkin) [62, 63]. Other genes associated with
mutations in PD include ubiquitin carboxy-terminal hydro-
lase L1, DJ-1, phosphatase and tensin homologue- (PTEN-)
induced kinase 1 (PINK1), leucine-rich-repeat kinase 2
(LRRK2), the nuclear receptor NURR1, HTRA2, and τ [7].
These mtDNA mutations associated with PD could be large-
scale rearrangements, point mutations, or microdeletions
[64–68]. The normal physiological function of α-synuclein
is to maintain synapse and plasticity but mutations caus-
ing overexpression of α-synuclein is neurotoxic, inducing
apoptosis [69, 70]. In vitro there is a strong connection
between α-synuclein ﬁbrillization and τ ﬁbrillization and
more evidence indicate frequent disease overlap between
the classical tauopathies (e.g., NFT formation in AD) and
synucleinopathies (e.g., Lewy body formation in PD) [71–
73].
Postmortem tissues from PD patients have shown evi-
dence that a defect in complex I of the mitochondrial
electron-transport chain in substantia nigra, resulting in
30–40% decrease in the activity may be the central cause
of sporadic PD [74]. The decreased activity could be
due to underproduction of certain complex 1 subunits,
complex 1 disassembly, or self-inﬂected oxidative damage
[75–77]. More evidence of oxidative stress and PD comes
from examination of substantia nigra region of human PD
brain showing oxidative damage to DNA and protein along
with immunocytochemical evidence for protein nitration
and glycation [60, 78–83]. Also the most important lipid
oxidation product 4-hydroxy-2-nonenal (HNE) was mod-
iﬁed in PD brains [84, 85]. One of the other causes of
sporadic PD include point mutations in α-synuclein leading
to deposition of Lewy bodies by altering posttranslational
modiﬁcation of α-synuclein [86]. Impaired mitochondrial
function, increased oxidative stress, and enhanced nigral
pathology induced by MPP+, a metabolite of MPTP (1-
methyl 4-phenyl-1, 2, 3, 6-tetrahydropyridine) inhibiting
complex 1 are the characteristics of the transgenic mice over-
expressing α-synuclein [87]. On the contrary, α-synuclein
null mice are resistant to MPTP indicating an important role
in mediating toxic eﬀects of MPTP [88].
Ubiquitin, another important protein found in Lewy
bodies of sporadic PD is associated with proteolytic stress
as ubiquitin-proteasome process is impaired by products
of oxidative damage like HNE [59, 89]. This also relates
to other genetic defects associated with familial PD; E3
ubiquitin ligase called parkin. Mitochondrial impairment
and increased oxidative stress is observed in parkin-null
Drosophila and mouse strains [90, 91]. Similar to mutations
in parkin, mutations in DJ-1 and PINK1 are also associated
with autosomal recessive juvenile PD [92–95]. Both, DJ-1
and PINK1 protect against cell death. DJ-1 acts as a negative
regulator of PTEN tumor-suppressor protein, increasing the
cell survival and also DJ-1 null mice are hypersensitive to
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expression prevents apoptosis under basal and staurospoine-
induced conditions [96].
Besides mutations, overexposure to dopamine or metals
like iron (Fe) and manganese (Mn) also plays an important
role in the pathology of sporadic PD. In cell culture,
dopamine is toxic to PC12 cell via oxidative stress, leading to
apoptosis [97]. Dopamine oxidation leads to the formation
of a known neurotoxin: 6-hydroxy-dopamine (6-OHDA)
[98]. Two stimulants methamphetamine (METH) and 3,
4-methylenedioxymetham-phetamine (MDMA) when taken
at very high dose also cause dopaminergic neurotoxicity
[99]. In PD brains, a very high level of iron is found
which increases with the severity of the disease [100]. High
iron overload could be due to sequestration by eosinophilic
protein aggregates and also iron has been implicated in the
promotion of α-synuclein aggregation [101].
From the above-stated various factors causing PD, it is
clear that PD not only results from a complex interplay
among genetic and environmental factors, but also aspects
of mitochondrial dysfunction and oxidative stress play a
very important role. For a better therapeutic strategy for
PD, all the causes and their interplay need to be taken into
consideration for a drug, targeting PD.
3.4. Oxidative Stress in HD. As previously mentioned, Hunt-
ington’sdisease(HD)isgeneticallyinheritedinanautosomal
manner. Clinically HD is characterized by psychiatric distur-
bances, progressive cognitive impairment, and choreiform
movements. Pathologically HD is characterized by loss of
long projection neurons, resulting in a progressive atrophy
of the caudate nucleus, putamen, and globus pallidus [102].
T h eH Dm u t a t i o ni sa ne x p a n s i o no fC A Gt r i n u c l e o t i d e
repeat within exon 1 of the huntingtin (HTT)g e n e ,a
cytoplasmic protein of unknown function [103]. Because the
CAG triplet codes for glutamine extension, upon mutation,
theproteinpresentsapolyglutaminetractattheN-terminus,
leading to a conformational change of the protein and
ultimately resulting in abnormalprotein-protein interaction.
Inhumans,adult-onsetHDoccurswhentherearemorethan
40 CAG repeats, compared to the normal number which is
less than 36 repeats. In juvenile cases the expansion goes
u pt o7 0r e p e a t so rm o r e[ 104]. Mutant HTT confers a
dominant “gain of function” to the protein, due to expanded
polyglutamine segment, ultimately leading to neurodegen-
eration [105]. Various lines of evidence indicate that one
of the major consequences of the gene expansion may be
mitochondrial metabolic defect resulting in impaired energy
metabolism [106]. Impaired mitochondrial energy possibly
increases more production of free radicals which in turn
leads to an increased oxidative damage.
Many recent evidences from HD patients indicate in-
volvementofmitochondrialdysfunctioninthepathogenesis.
HD patient brains reveal increased production of lactate in
the cerebral cortex and basal ganglia upon nuclear magnetic
resonance imaging spectroscopy [107, 108]. Another study
reported decreased complex I activity and no change in
the activities of complexes II-III and IV in platelets [109].
Biochemical studies of brain tissue from human HD brain
have shown multiple defects in the caudate: decreased
complex II and complex II-III activity with no alteration of
complex I or IV activities [110, 111]. Also ultrastructural
abnormalities in mitochondria have been described in HD
cortical tissue [112, 113]. Although oxidative stress does
not have a very profound eﬀect in HD compared to other
major neurodegenerative diseases, HD patients exhibit low
activityofcatalaseinskin ﬁbroblastcultures[114].Instudies
carried out on mutant HTT-knock-in mouse embryos,
signiﬁcant impairment in mitochondrial respiration and
ATP production was observed [115].
In summary, mutant HTT causes abnormal protein
interactions aﬀecting normal mitochondrial function lead-
ing to oxidative stress and other downstream excitotoxic and
inﬂammatory events, together resulting in neuronal death.
4. Deregulation of Cdk5 due to Oxidative Stress
Leading to Neurodegeneration
Aberrant phosphorylation caused by the deregulated activity
of cyclin dependent kinase 5 (Cdk5) has been closely
associated with various neurodegenerative diseases like AD,
ALS, HD, and PD. Cdk5, a proline-directed serine/threonine
kinase, plays multiple roles in neuron development, neu-
ronal survival, phosphorylation of cytoskeletal proteins and
synaptic plasticity [116, 117]. The active form of Cdk5 is
found primarily in the nervous system due to its activator
proteins p35 or p39 speciﬁcally expressed in neuronal cells
[118–120]. Activity of Cdk5 is tightly regulated and it plays
an important role in CNS development by phosphorylating
the speciﬁc serine or threonine site of numerous substrate
proteins that are closely associated with the neuronal
migration, synaptogenesis, and synaptic transmission as
well as synaptic plasticity. However, under various stressed
conditions like oxidative stress, mitochondrial dysfunctions,
excitotoxicity, Aβ exposure, calcium dyshomeostasis, and
inﬂammationleadtoriseintheintracellularCa2+.H ighCa 2+
concentration activates calpain which cleaves p35 to p25
forming a more stable yet hyperactive Cdk5/p25 complex
[119, 121–128]. Various cytoskeletal proteins are aberrantly
hyperphosphorylated by this complex eventually leading to
neuronal death/neurodegeneration [122, 123, 129–131].
4.1. Role of Cdk5 in AD. Cdk5 is activated by oxidative stress
in AD, resulting in hyperactive and aberrant Cdk5/p25 activ-
ity causing hyperphosphorylation of τ,n e u r o ﬁ l a m e n t( N F )
and other cytoskeletal proteins [123, 132, 133]. Oxidative
stress and mitochondrial dysfunction are one of the earliest
events in AD pathology preceding appearance of NFT [134].
Accumulation of Aβ in cortical neurons induces cleavage of
p35 to p25 resulting in activation of kinases and inhibition
of phosphatases proceeding NFT formation [21, 123]. Upon
neuronal insult with either Aβ or glutamate, primary cortical
neuronshaveshownenhancedCdk5activity.Aftertreatment
with inhibitors like roscovitine or Cdk5 inhibitory peptide
(CIP),cellsdisplayedreductioninhyperactiveCdk5[21,135,
136]. Also, cell culture results have shown that Aβ and gluta-
mate toxicity cause Cdk5 to promote mitochondrial damage
and induce p38 activation by increasing ROS [137, 138].6 Advances in Pharmacological Sciences
In AD brains signiﬁcant increase in p25 levels and activity
of Cdk5 and p38 is observed [139, 140]. Furthermore,
mitochondrialdepolarizationresultsinmoreROSformation
and Ca2+ release, both of which eventually activate Cdk5
[122, 127]. Therefore, hyperactivity of Cdk5 is involved
in promoting cell death via a feedback loop mechanism
by being an upstream regulator as well as a downstream
eﬀector of mitochondrial dysfunction [137]. More evidences
from cell culture studies have shown various substrates of
Cdk5 leading to more ROS production. Two such substrates
are peroxiredoxin-I (Prx-I) and peroxiredoxin-II (Prx-II)
belonging to the Prx family of peroxidases that under
physiological conditions eﬃciently scavenge ROS [141–144].
Cdk5-mediated phosphorylation of Prx-I and Prx-II reduces
their enzymatic activities resulting in ROS accumulation
within the cells [137].
Silencing Cdk5 via RNA interference (RNAi) using
lentiviral or adenoassociated viral vectors in the brains of
transgenic AD mouse models show reduction in phos-
phorylation of tau and decreased number of NFTs in
the hippocampus [145]. Besides being involved in hyper-
phosphorylation of tau and formation of NFTs, Cdk5/p25
has also been involved in phosphorylation of APP in its
cytoplasmic domain at Thr668 [146]. Increased APP Thr668
phosphorylation has been observed in p25 transgenic mice
compared to normal p35/Cdk5 activity [147]. These studies
taken together strongly suggest that Cdk5 activation may
be an early event in AD and therefore, could be used as a
potential therapeutic target for AD.
4.2. Role of Cdk5 in ALS. Aberrant Cdk5 hyperactivity
due to oxidative stress is also linked to motor neuron
degeneration and ALS by compromising the NF dynamics
[129]. In cultured neurons, when exposed to oxidative stress
via treatment with hydrogen peroxide, Cdk5 phosphorylated
the high molecular weight NF (NF-H). This inhibited NF
axonal transport and induced perikaryal accumulation of
NF phosphoepitopes normally conﬁned to axons [148–150].
Upon inhibition of Cdk5 activity with either roscovitine or
CIP, these eﬀects were prevented indicating role of Cdk5 in
ALSpathology [127].Mutations inSOD1are associated with
ALS and promote increased oxidative stress and increased
production of ROS [151, 152]. Transgenic mice expressing
mutant human SOD1 display increased ratio of p25/p35 in
addition to abnormal localization and hyperactivation of
Cdk5 [153]. Also, these mice have perturbed axonal trans-
port and display aberrant NF accumulation within perikarya
[154]. All these evidence suggests a major role of oxidative
stress-induced Cdk5 hyperactivity leading to perikaryal NF
phosphorylation inhibiting NF axonal transport causing
motor neuron degeneration.
4.3. Role of Cdk5 in PD. Evidence of Cdk5 hyperactivity
associated with PD comes from the studies involving gyrus
cinguli (brain region above corpus callosum) of PD patients
showing higher p25/p35 ratio due to calpain activation com-
pared to age-matchedcontrols [155]. As previously stated
parkin phosphorylation and ubiquitination may modulate
the formation of the Lewy bodies, relevant to the disease.
Transgenic mouse model studies have indicated Cdk5 as
a new regulator of the parkin ubiquitin-ligase activity
since serine 131 has been identiﬁed as the major Cdk5
phosphorylation site in parkin. The Cdk5 phosphorylation-
deﬁcient S131A parkin mutant displays increased autoubiq-
uitination and is more prone to aggregation upon pro-
teasome inhibition. Furthermore, this mouse increases the
formation of synphilin-1/α-synuclein inclusions indicating
that phosphorylation of parkin by Cdk5 decreases its E3
ubiquitin-ligase activity and regulates the formation of
cytosolic inclusions relevant to PD [156]. Phosphorylation
by Cdk5 may contribute to the accumulation of toxic parkin
substrates and decrease the ability of dopaminergic cells to
cope with toxic insults in PD.
4.4. Role of Cdk5 in HD. Contrary to the role of Cdk5
in above-mentioned neurodegenerative diseases like AD,
ALS, and PD, Cdk5 shows a neuroprotective role in HD.
As mentioned earlier cause of HD is the expansion in
polyQ stretch in the huntingtin (htt) protein. More than 40
polyQ tracts leads to htt protein misfolding, making it toxic
and resulting in formation of aggregates and cause disease.
Inhibiting polyQ aggregation alleviates the symptoms of HD
patients, as reported in Drosophila and mouse models of
HD [157, 158]. Short fragments of htt with expanded polyQ
repeats show greater toxicity and aggregation compared
with full-length mutant constructs and are suﬃcient to
cause cell death in cell culture or disease in animal models
[159, 160]. Thus, mutant htt cleavage either by caspases,
calpains, or other proteases resulting in toxic fragment
production may be an important rate-limiting step in HD
pathogenesis [160–162]. Various evidences have shown that
htt not only interacts and colocalizes with Cdk5 in cellular
membrane fractions but is also phosphorylated at Serine 434
leading to reduced caspase-mediated htt N-terminal cleavage
at residue 513, resulting in decreased aggregation [163].
Also, Cdk5 phosphorylates at Serine1181 and Serine1201
to prevent the gain of toxic activity [164]. These results
also suggest the ability of Cdk5 phosphorylation to protect
against htt cleavage, aggregation and toxicity, which are
compromised in cells expressing toxic fragments of htt
[163]. Another study carried out on cell lines and rat or
mouse cortical neuron cultures shows the kinase activity of
Cdk5/p35suppressinginclusionformationofpolyQproteins
by disrupting microtubules (MTs). Cdk5-dependent regula-
tion of MT organization is involved in the development of
aggregate formation and subsequent pathogenesis of polyQ
diseases [165]. This Cdk5 inhibition of htt aggregates oﬀers
a novel mechanism and hence could be used as a potential
therapeutic target for HD.
Figure 1 describes in brief the role of Cdk5 in physi-
ology as well as in pathology. Under healthy physiological
conditions, Cdk5 plays a very important role in various
neuronal functions. However, due to various stress and
insults, deregulated Cdk5 activity leads to pathological
condition.Advances in Pharmacological Sciences 7
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Figure 1: Summary of role of Cdk5 in physiology and pathology. Cdk5 is a proline-directed serine/threonine kinase and gets activated by
its neuron speciﬁc promoter p35. Under normal physiological (normal) conditions, Cdk5/p35 is involved with various roles in neuronal
development, cognition and memory, cell adhesion, phosphorylation of cytoskeletal proteins, and synaptic plasticity. When the neurons are
stressed due to various insults like oxidative stress, inﬂammation, mitochondrial dysfunction, or toxicity due to Aβ or glutamate, there is an
increase in Ca2+ leading to activation of calpain, a protease. Calpain cleaves p35 to p25 deregulating Cdk5 activity as p25 forms a hyperactive
and more stable complex with Cdk5. Cdk5/p25 activity causes aberrant phosphorylation of various proteins leading to conformational
changes inducing gain of toxic function. Misfolded proteins lead to self-aggregation thereby overwhelming the system by blocking transport
and disrupting synaptic activity. This ultimately leads to degeneration of neurons and ﬁnally be the cause of various neurodegenerative
diseases like AD, ALS, PD, and HD.
5. Conclusions
Recentevidenceshavegreatlyincreasedourknowledgeabout
the AD, ALS, PD, and HD, major neurodegenerative diseases
assessed above. From various studies, it has become evident
that all the neurodegenerative diseases are to some extent
multifactorial, and oxidative stress is inevitably intertwined
with the disease mechanisms. Besides biological factors like
inﬂammation, excitotoxicity, and to a certain extent role of
genes involved in sporadic cases, environmental contribu-
tions like diet and lifestyle are also important contributing
factors for the occurrence of these diseases.
These disorders have many common factors. One such
factor is the deregulation of Cdk5 as depicted in Figure 1.
Cdk5 plays a very important role in these neurodegenerative
disorders. In a normal physiological condition, Cdk5 along
with its neuron speciﬁc activator p35 is involved in various
neuronal processes necessary for normal function. Under
neuronal stress and insults which could be due to many
factors like oxidative stress and release of ROS, Aβ or gluta-
matetoxicity,inﬂammation,andmitochondrialdysfunction,
there is intracellular increase in Ca2+ concentration. This
leads to the activation of proteases-like Calpain which
cleaves p35 into p25. Association of p25 with Cdk5 leads to
the diseased condition as Cdk5/p25 activity is deregulated
causing aberrant hyperphosphorylation of various proteins
like neuroﬁlament, τ, parkin, α-synuclein, and Huntingtin.
Hyperphosphorylation of these proteins leads to misfolding
and aggregation causing conformational changes. Misfolded
proteins self-aggregate disrupting transport and normal
synaptic activity ultimately leading to neuronal degeneration
and pathology.
Since oxidative stress is involved in neurodegeneration,
selecting antioxidants, metal chelators, or other compounds
boosting endogenous enzymatic and nonenzymatic defense
mechanism seems to be an obvious choice as a treat-
ment to these disorders. However, using antioxidants like
Vitamin E (tocopherol) and others as a therapeutic target8 Advances in Pharmacological Sciences
comes with a caveat as most antioxidants have metal-
reducing capacity. Therefore, devising a successful regimen
of antioxidants to retard the progression of these diseases
remains a complicated goal. Besides using anti-oxidants as
therapeutic targets, Cdk5 with all its involvement in the
above mentioned neurodegenerative diseases seems to be
potential and ideal candidate to be used as therapeutic target
for neurodegenerative diseases.
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